SMALL CELL LUNG CANCER

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has returned or not responded to therapy. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is…

This study tests whether a combination of drugs (irinotecan liposome, platinum, an immune checkpoint inhibitor, and anlotinib) can help control extensive small cell lung cancer after initial treatment. About 31 adults with this advanced lung cancer will receive the drug combo as …

This study tests a new combination of two drugs, HLX43 and serplulimab, in 120 people with advanced lung cancer that has spread or cannot be removed by surgery. The goal is to find the best dose and see if the treatment can shrink tumors. Participants must be between 18 and 75 ye…

This study tests an experimental drug called FHD-286 in 20 adults with a specific type of small-cell lung cancer (POU2F3-positive) that has worsened after at least one prior treatment. Participants take a daily pill in 21-day cycles. The main goal is to see if the drug shrinks tu…

This study tests a drug called tarlatamab in 35 adults with small cell lung cancer that has spread to the brain but is not causing symptoms. Participants must have already had chemotherapy. The goal is to see if the drug can shrink or control brain tumors. This is a phase 2 trial…

This study is for elderly patients (65+) or those in poor health with small cell lung cancer. It tests a combination of two drugs—adebrelimab (an immunotherapy) and oral etoposide (chemotherapy)—to see if it can control the cancer and improve survival. The goal is to find a gentl…

This study tests a new treatment for people with advanced small-cell lung cancer whose cancer got worse after initial therapy. The treatment combines a chemotherapy drug called nab-paclitaxel with targeted radiation. The goal is to see if this combination can slow cancer growth a…

This early-phase study tests whether adding an experimental drug (DSP-0390) to standard maintenance immunotherapy (atezolizumab) can help keep extensive-stage small cell lung cancer from progressing. About 20 adults whose cancer did not worsen after initial chemotherapy plus immu…

This study tests a new drug called SYS6090 combined with chemotherapy or other targeted drugs in people with advanced lung cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 596 adults aged 18 to 75 with non-smal…

This study tests a combination of limertinib (a targeted pill) plus two chemotherapy drugs (carboplatin and etoposide) in 30 adults with a specific type of lung cancer. These patients had non-small cell lung cancer with an EGFR mutation, but after initial targeted therapy stopped…

This study tests a new drug called DXC006 combined with either immunotherapy or chemotherapy in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumors or delays cancer growth. Participants must be 18-75 years old and …

This study will observe 300 people with advanced solid tumors (like lung or gastrointestinal cancers) who receive adebrelimab combined with other treatments. The goal is to see how safe and effective these combinations are in everyday medical practice. Researchers will track side…

This study observes how patients with advanced small cell lung cancer are treated in everyday hospital settings and how they respond. About 96 adults will join, and researchers will collect data from medical records and regular check-ins every 3 months. No experimental treatments…

This study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers want to learn more about how the drug works in real patients, find markers that might predict side effects, and understand why some patient…

This study collects blood and tissue samples from 110 adults with advanced lung, head/neck, or mesothelioma cancers. The samples will be stored in a biobank to help scientists study genetic changes and find better ways to predict treatment outcomes. Participants donate samples bu…